Glaucoma clinical trials
46 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Electrical Stimulation for the Treatment of Optic Neuropathies
- Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
- Hyperbaric Oxygen Therapy for Optic Neuropathies
- Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
- Topical Insulin for Glaucoma
- Pilocarpine Use After Kahook Goniotomy
- Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
- Glaucoma Laser Assessment of Stability and Sustainability
- Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
- The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma
- Stem Cell Ophthalmology Treatment Study II
- Retinal Blood Flow and Autoregulation
- The Glaucoma and Retinopathy Screening Study
- Virtual Reality Visual Field Testing as an Alternative in Childhood Eye Disease
- Glaucoma Screening to Enhance At-Risk Californians' Health
- Ocular Blood Flow Imaging for Glaucoma Assessment
- Automated Applanation Tonometry - Updated
- Village-Integrated Eye Worker Trial II
- A More Engaging Visual Field Test to Increase Use and Reliability in Pediatrics
- Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
- Glaucoma Related Quality of Life
- Change in IOP Fluctuation After DSLT
- To Study Ocular Outflow Dynamics of the Eye Using Intraoperative Tonographic Biometry and Assess Its Predictive Value in Improving Postoperative Outcomes.
- Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy
- Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
- Data Gathering for A10900
- Optimize Pediatric OCT Imaging
- Assessment of the Ocular Microbiome in Health and Disease
- Tied Tube Trial in Glaucoma Surgery
- Novel Glaucoma Diagnostics
- Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension
- IOP Elevation Study
- Comparison of Intraocular Pressure Measurement With the Novel TonoVera Device With Other Commonly Used Devices
- Community Based Treatment for (ComBaT) Glaucoma
- Advancing Pediatric Retinal Imaging With Auto-aligned OCT
- Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2
- Strategies for Improving Linkage-to-Care After Eye Disease Screening
- Rocklatan Retinal Perfusion OCT Study
- Topical Insulin for Glaucoma (TING2)
- Glaucoma Drop Aids Part 2
- Know Your Pressures NYC
- Effectiveness of a Large Language Model-Based Educational Tool on Visual Field Test Reliability in Glaucoma Patients
- Electrical Stimulation of the Optic Nerve in Patients With Glaucoma.
- Functional and Structural Imaging for Glaucoma
- Eye Pressure Lowering Surgery
- CLAD Deconvolved PERG Responses in Glaucoma Patients
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Glaucoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.